Educational EHA-LYG / GHSG Joint Educational “Emerging Therapeutic Concepts in B-Cell Lymphomas” Introduction

Educational EHA-LYG / GHSG Joint Educational “Emerging Therapeutic Concepts in B-Cell Lymphomas” Molecular and microenvironmental vulnerabilities of B-cell lymphomas

Sirpa Leppä

Educational EHA-LYG / GHSG Joint Educational “Emerging Therapeutic Concepts in B-Cell Lymphomas” Is there a role for CAR T-cell therapy in first-line Tx of indolent lymphoma?

Marie Jose Kersten

Educational EHA-LYG / GHSG Joint Educational “Emerging Therapeutic Concepts in B-Cell Lymphomas” Who needs bispecific antibodies as first-line treatment in aggressive lymphoma?

Catherine Thieblemont

Educational EHA-LYG / GHSG Joint Educational “Emerging Therapeutic Concepts in B-Cell Lymphomas” How to implement novel ADCs in the first-line treatment of lymphoma

Pier Luigi Zinzani

Educational EHA-LYG / GHSG Joint Educational “Emerging Therapeutic Concepts in B-Cell Lymphomas” Perspectives of small molecule based first-line therapy of LBCL

Theodoros Vasilakopoulos

Educational EHA-LYG / GHSG Joint Educational “Emerging Therapeutic Concepts in B-Cell Lymphomas” Treatment and Trial Landscape for Malignant Lymphoma in China

Yuqin Song

Scientific Session Limited Stages IIntro: Treatment concepts in early-stage HL

Marc André

Scientific Session Limited Stages Viewpoint: Systemic Therapy only in the future?

Ranjana Advani

Scientific Session Limited Stages Viewpoint: CMT (is it there to stay?)

Joachim Yahalom

Scientific Session Limited Stages Factors driving treatment intensity in the whole cohort of patients with early-stage favorable (I-IIA), nonbulky Hodgkin Lymphoma enrolled in the RAFTING trial (NCT 04866654).

Andrea Gallamini

Scientific Session Limited Stages Nodular lymphocyte predominant Hodgkin lymphoma in the Nordic countries – characteristics, treatment and survival

Ingrid Glimelius

Scientific Session Limited Stages Serum TARC Dynamics Correlate with Clinical Response and Metabolic Tumor Volume During Anti-PD1-Based First-Line HL Treatment in The GHSG Phase II NIVAHL Trial

Wouter Plattel

Satellite Symposium The evolving role of BTKis in the treatment of B-cell lymphomas Welcome and Introduction

Christian Buske

Satellite Symposium The evolving role of BTKis in the treatment of B-cell lymphomas BTKis in indolent lymphomas (FL, MZL)

Catherine Thieblemont

Satellite Symposium The evolving role of BTKis in the treatment of B-cell lymphomas BTKis in WM

Christian Buske

Satellite Symposium The evolving role of BTKis in the treatment of B-cell lymphomas BTKis in MCL

David Lewis

Satellite Symposium The evolving role of BTKis in the treatment of B-cell lymphomas Future developments (CDAC, BCL2, anti PD1/PDL1)

Anna Maria Frustaci

Satellite Symposium The evolving role of BTKis in the treatment of B-cell lymphomas Panel discussion, audience Q&A

Satellite Symposium The evolving role of BTKis in the treatment of B-cell lymphomas Closure and farewell

Christian Buske

Main Program Opening and Award Ceremony Welcome Address

Peter Borchmann, Volker Diehl

Main Program Opening and Award Ceremony Award Ceremony

Sven Borchmann, Paul J. Bröckelmann, Peter Borchmann, Dennis Eichenauer

Main Program Opening and Award Ceremony Keynote Lecture

Linda Partridge

Scientific Session Pediatric and Adolescent Treatment Concepts Recent achievements and future goals in Pediatric and Young Adult HL: COG Perspective

Sharon Castellino

Scientific Session Pediatric and Adolescent Treatment Concepts Recent achievements and future goals in Pediatric and Young Adult HL: EuroNET-PHL Perspective

Christine Mauz-Körholz

Scientific Session Pediatric and Adolescent Treatment Concepts Appropriate endpoints for future trials in Pediatric and Young Adult HL, and opportunities for harmonization

Jamie Flerlage, Kara Kelly

Scientific Session Pediatric and Adolescent Treatment Concepts EFFICACY and TOLERABILITY in DECOPDAC21 versus COPDAC28 in PEDIATRIC INTERMEDIATE and ADVANCED STAGE CLASSICAL HODGKIN LYMPHOMA: INTERIM RESULTS of the EURONET-PHL-C2 RANDOMIZED STUDY

Dieter Körholz

Scientific Session Pediatric and Adolescent Treatment Concepts Progression-Free Survival (PFS) with Nivolumab-AVD is superior to Brentuximab Vedotin-AVD with 2-year follow-up of S1826 in Adolescent Advanced Stage (AS) Classic Hodgkin Lymphoma (cHL)

Sharon Castellino

Scientific Session Pediatric and Adolescent Treatment Concepts Updated Results from the Phase 2 KEYNOTE-667 Study: Pembrolizumab (pembro) in Children and Young Adults With Low-Risk Classical Hodgkin Lymphoma (cHL) and Slow Early Response (SER) to Front-Line Chemotherapy (chemo)

Kara Kelly

Scientific Session Biology & Microenvironment Pathogenesis of HL

Ralf Küppers

Scientific Session Biology & Microenvironment Multimodal characterization of cHL

Christian Steidl

Scientific Session Biology & Microenvironment Characterization of cancer-associated fibroblasts and their spatial architecture reveals heterogeneity and survival associations in classical Hodgkin lymphoma

Kristiina Karihtala

Scientific Session Biology & Microenvironment Circulating tumor DNA sequencing facilitates biological classification and individualized risk stratification in patients with Hodgkin lymphoma

Michel Heger

Scientific Session Biology & Microenvironment Distinct cell state ecosystems for nodular lymphocyte-predominant Hodgkin lymphoma

Michael Binkley

Scientific Session Biology & Microenvironment Multi-Dimensional Profiling Unveils Distinct Molecular Subtypes in Classic Hodgkin Lymphoma

Tomohiro Aoki

Satellite Symposium New concepts for the treatment of B-cell lymphomas B-cell lymphoma pathology – illustrated for non- pathologists

Wolfram Klapper

Satellite Symposium New concepts for the treatment of B-cell lymphomas Classical Hodgkin Lymphoma - Development of immune checkpoint inhibition beyond PD-1 blockade

Peter Borchmann

Satellite Symposium New concepts for the treatment of B-cell lymphomas Diffuse Large B-cell Lymphoma - The current and future role of ADC in the context of immunotherapies

Sascha Dietrich

Scientific Session Older Patients Implementing Frailty Assessment for Treatment Guidance in HL

Sarah Rutherford

Scientific Session Older Patients Optimal Use of Targeted Agents to Address Unmet Need in Older HL

Graham Collins

Scientific Session Older Patients A simplified frailty score predicts outcome in older patients with classical Hodgkin lymphoma treated with curative intent

Kjersti Lia

Scientific Session Older Patients Characterisation of older Hodgkin Lymphoma patients using UK registry data from 1997-2023

Aisling Barrett

Scientific Session Older Patients Feasibility and Efficacy of PET-guided BrECADD in Older Patients with Advanced-Stage classical Hodgkin Lymphoma: The Older Cohort of the International GHSG HD21 Trial

Justin Ferdinandus

Scientific Session Older Patients Nivolumab-AVD improves 2-year progression-free and overall survival compared to Bv-AVD in older patients aged ≥60 years with advanced stage classical Hodgkin lymphoma (cHL) enrolled on SWOG S1826

Sarah Rutherford

Satellite Symposium Real world impact: bridging between clinical trial and real world experience in stages III & IV 1L Hodgkin Lymphoma Spotlight on ECHELON-1: 7-year survival data

John Radford

Satellite Symposium Real world impact: bridging between clinical trial and real world experience in stages III & IV 1L Hodgkin Lymphoma Real-world insights: frontline treatment of stages III & IV cHL

Chiara Rusconi

Satellite Symposium Real world impact: bridging between clinical trial and real world experience in stages III & IV 1L Hodgkin Lymphoma Q&A

Satellite Symposium Real world impact: bridging between clinical trial and real world experience in stages III & IV 1L Hodgkin Lymphoma cHL in the real-world: a case study approach

Carolina Valeria Mahuad, John Radford

Scientific Session Advanced Stages Individualized treatment de-escalation improves overall outcomes

Peter Borchmann

Scientific Session Advanced Stages Immune-chemotherapy overcomes the need for individualization

Jonathan Friedberg

Scientific Session Advanced Stages 2-Year Follow-up of the S1826 Study Confirms Improved Progression-Free Survival with Nivolumab-AVD Compared to Brentuximab Vedotin-AVD in Advanced Stage Classic Hodgkin Lymphoma

Alex Herrera

Scientific Session Advanced Stages Development and application of a validated MRD assay in Hodgkin Lymphoma

Julia Mattlener

Scientific Session Advanced Stages EORTC-1537-COBRA: PHASE II STUDY OF VERY EARLY FDG-PET-RESPONSE ADAPTED TARGETED THERAPY FOR ADVANCED HODGKIN LYMPHOMA. PRIMARY ANALYSIS INCLUDING VALUE OF QUANTITATIVE PET ASSESSMENT AND TARC DYNAMICS

Martin Hutchings

Scientific Session Advanced Stages Metabolic tumor volume after two cycles of chemotherapy in patients treated for advanced-stage Hodgkin Lymphoma: analysis of the German Hodgkin Study Group phase III HD18 and HD21 trials

Justin Ferdinandus

Scientific Session NLPHL NLPHL: HL, NHL or something else?

Sylvia Hartmann

Scientific Session NLPHL First-line treatment of NLPHL with HL-directed approaches

Dennis Eichenauer

Scientific Session NLPHL Treatment of NLPHL with NHL-directed approaches

Graham Collins

Scientific Session NLPHL Q&A

Sylvia Hartmann, Eichenauer Dennis, Graham Collins

Scientific Session Living Beyond Lymphoma Late consequences of drugs used in the modern era of treatment for HL (to include anthracyclines, bleomycin, checkpoint inhibitors, ADCs)

Stephen Ansell

Scientific Session Living Beyond Lymphoma Starting Living beyond Lymphoma with HL diagnosis

Karolin Behringer, Maximilian Büttner

Scientific Session Living Beyond Lymphoma Participation in and (cost-)effectiveness of the Dutch HL survivorship care program

Annelies Nijdam, Berthe Aleman

Scientific Session Living Beyond Lymphoma A priori estimation of mediastinal toxicities after radiotherapy for Hodgkin Lymphoma - A secondary analysis of the HD16/17 Trial by the German Hodgkin Study Group using normal tissue complication probability calculations

Michael Oertel

Scientific Session Living Beyond Lymphoma Concordance between late effects reported by physicians and patients in a cohort of long-term Hodgkin lymphoma survivors: an analysis of data from nine consecutive EORTC-LYSA trials

Sidsel Juul

Scientific Session Living Beyond Lymphoma Novel 3D speckel tracking imaging modality in detecting cardiac toxicity in asymptomatic pediatric HL survivors

Zeinab Salah Seliem

Scientific Session Relapsed & Refractory HL Updated approach to second-line treatment

Alison Moskowitz

Scientific Session Relapsed & Refractory HL Emerging strategies to overcome anti-PD1 resistance

Stephen Ansell

Scientific Session Relapsed & Refractory HL Implementing raditoherapeutic concepts in rrHL care

Christian Baues

Scientific Session Relapsed & Refractory HL Brentuximab Vedotin - ESHAP Significantly Increases the Metabolic Complete Remission Rate versus ESHAP in Relapsed Classical Hodgkin’s Lymphoma. Final Results of the BRESELIBET Prospective Trial.

Anna Sureda

Scientific Session Relapsed & Refractory HL Longitudinal circulating tumor DNA sequencing may predict the response to PD1 blockade therapy in relapsed/refractory classical Hodgkin Lymphoma patients

Francesco Corrado

Scientific Session Relapsed & Refractory HL Pembrolizumab maintenance instead of autologous hematopoietic cell transplantation for patients with relapsed or refractory Hodgkin lymphoma in complete response after pembrolizumab, gemcitabine, vinorelbine, and liposomal doxorubicin

Alison Moskowitz

Main Program Closing remarks Workshop Report

Sally Barrington, Sven Borchmann, Carsten Kobe, Wouter Plattel, Davide Rossi

Main Program Closing remarks Best of ISHL13

Ranjana Advani

Main Program Closing remarks Farewell

Peter Borchmann